









Markets
/
Stocks
/
nasdaq-bfri
/

Biofrontera Inc

BFRI

0.795USD

-0.015-1.86%

Market hours （ET）Quotes delayed by 15 min

317.88KMarket Cap

LossP/E TTM



Biofrontera Inc

0.795

-0.015-1.86%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Biofrontera Inc

Currency: USD Updated: 2026-03-27

Key Insights

Biofrontera Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 104 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.00.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Biofrontera Inc's Score

Industry at a Glance

Industry Ranking

104 / 157

Overall Ranking

293 / 4542

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Biofrontera Inc Highlights

StrengthsRisks

Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 22.41% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 41.70M.

Undervalued

The company’s latest PE is -0.79, at a low 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 113.95K shares of this stock.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

6.000

Target Price

+640.92%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Biofrontera Inc is 7.23, ranking 116 out of 157 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 17.10M, representing a year-over-year increase of 36.16%, while its net profit experienced a year-over-year increase of 504.01%.

Score

Industry at a Glance

Previous score

7.23

Change



Financials

5.15

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.20

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.62

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.20

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Biofrontera Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Biofrontera Inc is 6.90, ranking 106 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is -0.79, which is -244.02% below the recent high of 1.14 and -4161.63% above the recent low of -33.70.

Score

Industry at a Glance

Previous score

6.90

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 104/157

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Biofrontera Inc is 8.00, ranking 57 out of 157 in the Pharmaceuticals industry. The average price target is 6.00, with a high of 9.00 and a low of 3.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

6.000

Target Price

+640.92%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

Biofrontera Inc

BFRI

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Biofrontera Inc is 4.11, ranking 148 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 0.93 and the support level at 0.73, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

3.83

Change

0.28

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.013

Sell

RSI(14)

43.207

Neutral

STOCH(KDJ)(9,3,3)

25.862

Neutral

ATR(14)

0.054

High Vlolatility

CCI(14)

-135.014

Sell

Williams %R

70.515

Sell

TRIX(12,20)

-0.155

Sell

StochRSI(14)

42.080

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.822

Sell

MA10

0.848

Sell

MA20

0.858

Sell

MA50

0.875

Sell

MA100

0.851

Sell

MA200

0.875

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Biofrontera Inc is 3.00, ranking 93 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 28.39%, representing a quarter-over-quarter increase of 17.66%. The largest institutional shareholder is The Vanguard, holding a total of 113.95K shares, representing 0.98% of shares outstanding, with 908.56% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Rosalind Advisors, Inc.

644.39K

AIGH Capital Management, LLC.

914.21K

Hewlett Fund, L.P.

550.22K

Biofrontera AG

400.00K

Lytton (Laurence W)

306.70K

-42.75%

Armistice Capital LLC

291.15K

+94.10%

Luebbert (Hermann)

152.71K

+903.95%

Worth Venture Partners, LLC

249.36K

-33.41%

Leffler (Eugene Frederick)

87.50K

The Vanguard Group, Inc.

Star Investors

14.92K

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Biofrontera Inc is 1.92, ranking 139 out of 157 in the Pharmaceuticals industry. The company's beta value is 0.64. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.